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Abstract
Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the
presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis
or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct
clinic-pathologic entity with different cytogenetic and molecular findings. The clinical course is
aggressive with short remissions and survival duration. The diagnosis is based upon the
percentage (≥ 20%) and absolute number (≥ 2 × 10 9/L) of plasma cells in the peripheral blood. It
is proposed that the thresholds for diagnosis be reexamined and consensus recommendations are
made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin
promptly and have high clinical activity leading to rapid disease control in an effort to minimize
the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are
recommended followed by high-dose therapy with autologous stem-cell transplantation (HDT/
ASCT) if feasible. Allogeneic transplantation can be considered in younger patients. Prospective
multicenter studies are required to provide revised definitions and better understanding of the
pathogenesis of PCL.
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INTRODUCTION
More than a century ago, the first case of plasma cell leukemia (PCL) was recognized by
Gluziński and Reichenstein1. This uncommon form of clonal plasma cell dyscrasia is the
most aggressive variant of the human monoclonal gammopathies and it has been defined by
the presence of more than 20% plasma cells in peripheral blood and an absolute plasma cell
count greater than 2×109/L2,3. The incidence of PCL ranges between 2% and 4% of patients
with multiple myeloma (MM)4-7. PCL is classified as primary when it presents “de novo” in
patients with no evidence of previous MM and as secondary when it is observed as a
leukemic transformation of relapsed or refractory disease in patients with previously
recognized MM8. 60-70% of PCL are primary, and the remaining 30-40% are secondary9.
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More recent data suggest that there is an increasing incidence of secondary PCL, now
accounting for about 50% of the cases7. The aim of this article is to provide a consensus on
the diagnostic criteria for PCL, response criteria, and treatment recommendations for
primary PCL based upon a critical review of: 1) presenting features, 2) biological aspects
including cellular adhesion mechanisms, molecular genetics and bone marrow milieu
factors, 3) response criteria, and, finally 4) current treatment approaches, including
hematopoietic stem cell transplantation.
PRESENTING CLINICAL FEATURES
Because of the relative low incidence and prevalence of this entity, most clinical data come
from isolated case reports and small retrospective studies9,10. No prospective series have
been published and only seven reports including more than 20 patients have been
identified3-7,11-13. The main clinical and laboratory features, response to therapy and
survival of patients with primary PCL reported in these articles are summarized in Table 1.
The median age ranged between 52 and 65 years, about 10 years younger than the median
age of 65 to 70 years observed in the general myeloma population14 and in secondary PCL7.
However, in an epidemiology study including 291 patients diagnosed between 1973 and
2004, the median age was 67 years6. Although the data is limited, it appears that, as for MM,
PCL is more common in African Americans than in Caucasians15. Primary PCL has a more
aggressive clinical presentation than MM including a higher tumor burden. Patients may
present with symptoms due to profound anemia, hypercalcemia or bleeding diathesis due to
thrombocytopenia. On physical examination, patients may exhibit a higher prevalence of
organomegaly with involvement of the liver, spleen, lymph nodes, pulmonary findings
associated with pleural effusions, neurologic deficits due to central nervous system
involvement, pallor, petichae and palpable extramedullary soft-tissue plasmacytomas
(Figures 1 and 2). In contrast, the presence of lytic bone lesions is lower than that observed
in MM7. Fewer IgA cases than for MM patients were found in some studies, and there was
an unexpectedly low proportion of patients with IgG-type M-protein3 in one series. In
contrast, the proportion of patients with light-chain disease ranges from 26% to 44%,
whereas in general myeloma series the proportion of patients with Bence Jones myeloma is
only 15%14. Bone marrow examination will often demonstrate extensive bone marrow
plasma cell infiltration, with anaplastic or plasmablastic morphology (Figure 3), resulting in
a reduced bone marrow reserve, with a greater incidence of anemia and thrombocytopenia as
well as fewer normal plasma cells. Also, reflecting this aggressive clinical presentation, a
higher proportion of patients with primary PCL have significant leukocytosis, as well as
elevated lactate dehydrogenase (LDH) and β2-microglobulin serum levels. In fact, patients
with MM usually show normal or moderately increased LDH serum levels, with a
significant LDH elevation only observed in patients with high tumor load (43%)16.
Physicians must be aware of a potential tumor lysis syndrome given the high tumor burden
and elevated proliferative index. Thus, serum uric acid, calcium, phosphorous and serum
creatinine levels must be monitored. Importantly, similarly to acute leukemias, the
progression of disease is very rapid (weeks). Rare findings, such as hemophagocytic
syndrome17, hyperammonaemia18 or expression of solid tumor markers (CA125 and
CA15.3)19 have also been reported.
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Primary PCL is a distinct clinic-pathologic entity from MM because its presenting features
and its natural history including response to chemotherapy and poorer prognosis9.
Reinforcing this fact, the PCL pattern always reappears at the time of relapse, whereas
secondary PCL occurs only in 1-2% of advanced and refractory MM patients who evolve
into a leukemic phase with an aggressive clinical picture. In contrast, the constellation of
adverse biologic prognostic factors in patients with advanced and refractory myeloma
leading to a secondary PCL is a multistep process. Thus, primary and secondary PCL are
two distinct clinical and biologic entities that only share the features of plasma cells
circulating in the peripheral blood and an ominous clinical course.
Consensus:
Primary PCL is observed in younger patients than MM, with a increased incidence
of light-chain only (Bence Jones) type. The clinical picture is characterized by an
aggressive clinical presentation with high tumor burden, high proliferative index
(i.e. S-phase DNA), rapid clinical course, leukocytosis, extramedullary
involvement, marked bone marrow infiltration by immature plasma cells and high
LDH serum levels. Finally, the presentation of relapsed primary PCL routinely
mimics the initial clinical picture.
DIAGNOSTIC CRITERIA
The original diagnostic criteria of PCL were established in 1974 by Noel and Kyle, requiring
both more than 20% circulating plasma cells and an absolute count greater than 2×109/L
plasma cells in peripheral blood. These criteria provide a framework to define this disease
entity along with associated universal poor clinical outcome. These criteria have not been
evaluated prospectively to determine if a need for any modification is required.
What degree of circulating plasmacytosis should be used for defining PCL?
The control mechanisms by which plasma cells initially remain predominantly confined to
the bone marrow, only rarely entering the blood stream, are poorly understood. In fact, a low
proportion of plasma cells can be detected in peripheral blood in patients within the entire
spectrum of plasma cell dyscrasias including newly diagnosed MM, smoldering MM and,
exceptionally, in monoclonal gammopathy of undetermined significance (MGUS)20,21. It is
also important to recognize that the presence of circulating plasma cells is not always
indicative of PCL, since the presence of a significant number of polyclonal peripheral blood
plasma cells can be transiently observed in non-malignant conditions, such as severe sepsis,
infectious mononucleosis and, particularly, serum sickness22,23. In this light, peripheral
blood flow cytometry is important to demonstrate clonality of the plasma cells, and exclude
other lymphoproliferative diseases including low grade B cell or lymphoplasmacytic
lymphoma.
Do we need both an absolute value of circulating plasma cells and a percentage of WBC?
The criteria developed by Kyle2, requiring both more than 20% circulating plasma cells and
an absolute count greater than 2×109/L plasma cells in peripheral blood seems too restrictive
and the degree of peripheral plasmacytosis merits to be reconsidered.
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In many series only one of these two criteria was considered sufficient for the diagnosis of
PCL7,24-26. Patients with significant treatment exposure and poor bone marrow reserve have
baseline leukopenia and may not meet absolute criteria but may meet percentage criteria.
Probably only one of these criteria should be sufficient for the diagnosis of this entity. The
definition of PCL was not discussed in the recent International Myeloma Workshop
Consensus27, though it is well accepted that the presence of PCL constitutes an unfavorable
prognostic factor and that it is a subset of high risk myeloma28 with an especially poor
outcome.
Should we standardize methods to detect circulating plasma cells in peripheral blood?
The correct and timely diagnosis of PCL is dependent upon the ability of the pathologist to
screen and recognize plasma cells in the peripheral blood smear. Hematologists and
pathologists should be aware of the clinical relevance of a careful morphological
examination of peripheral blood smears in order to exclude the presence of circulating
plasma cells.
With all the considerations above, the diagnostic criteria for PCL should be revisited. The
current definition, even when only one of the two criteria is required, may underestimate its
real frequency. In any given patient, the presence of few circulating plasma cells
demonstrated by conventional morphology is still a marker for a highly proliferative and
aggressive process. Patients with an “early” PCL can rapidly develop full-fledged PCL in
the absence of treatment. In this regard, the current proposal for prospective studies is to
investigate if lower values (such as 5% or more plasma cells in peripheral blood and/or an
absolute peripheral blood plasma cell count ≥0.5×109/L) have the same prognostic impact as
historical criteria. Additional criteria to detect an early PCL process, which would allow
earlier intervention and therefore change the natural history of the disease, are warranted, for
example incorporating flow cytometry to detect clonal plasma cells and DNA content
analysis, cytogenetics and, ideally, novel molecular markers.
Consensus: Careful examination of peripheral blood by conventional microscopy
should be done in all patients with MM who present with a clinical scenario
suspicious of PCL, such as leukocytosis and an elevated LDH. If there are more
than 20% circulating plasma cells and/or an absolute count greater than 2×109/L
plasma cells, the diagnosis of PCL should be established according to the present
criteria. However, lower peripheral blood plasma cell counts (i.e. ≥5% peripheral
blood plasma cells and/or an absolute number ≥0.5×109/L) should be recorded in
order to revisit the diagnostic criteria of PCL and prospectively analyze the biology
and the clinical course of these patients. Additional methods including flow
cytometry to detect early PCL should be a high priority and warrant further studies,
encouraging prospective multi-center efforts in newly diagnosed patients.
BIOLOGY OF PCL
Immunophenotype
While the main plasma cell markers (CD38 and CD138) are equally expressed in MM and
PCL samples, the multiparametric flow cytometry shows a different pattern in PCL when
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compared with plasma cells from MM. In this regard, a higher expression of CD20 antigen5
and lower CD9, CD117, CD56 and HLA-DR is observed. CD28 is more frequently
expressed in secondary PCL29. This is consistent with the fact that the acquisition of CD28
antigen on plasma cells correlates with increased plasma cell proliferation and disease
progression29. The increased CD27 expression in PCL has been linked to activation of an
antiapoptotic pathway30,31. Furthermore, it has recently been shown that CD27
overexpression can lead to the activation of the nuclear factor κB (NF-κB) resulting in
antiapoptotic enhancement30. This may have therapeutic implications since NF-κB, which
plays a crucial role in the survival of malignant plasma cells, is inhibited by bortezomib and
other newer proteasome inhibitors. In addition, CD23 has been reported to be associated
with the presence of t(11;14)32. When compared with the studies performed on MM, the
immunophenotypic information at diagnosis as well as on the minimal residual disease
follow-up in PCL is really limited.
Mechanisms of extramedullary spread
Plasma cell dyscrasias are characterized by a proliferation of plasma cells with a strong
dependence on the bone marrow microenvironment33. The bone marrow microenvironment
plays a key role in the pathogenesis of MM by triggering signalling cascades which mediate
myeloma cell proliferation, migration and survival, with all of these contributing to
myeloma growth and to the homing of malignant plasma cells within the bone marrow.
Disruption of these mechanisms could be crucial for the unique biology of PCL. A number
of adhesion molecules have been involved in the egression of plasma cells to the peripheral
blood stream. The lack of CD56 antigen5,29, a neural cell adhesion molecule, which is
important in anchoring plasma cells to the bone marrow stroma and likely impairs their
circulation to peripheral blood as well as their migration to extramedullary sites, is a
frequent finding as in myeloma with t(14;16). In addition, it can result in a weaker myeloma
cell interaction and increased secretion of metalloproteinase-9 (MMP-9). Downregulation of
CD106 and activated-CD2934 and decreased expression of the surface molecules HLA-1
and CD40 in PCL versus MGUS cells35 are also in this sense. A higher expression of CD54
on plasma cells as compared to adhesion molecules CD11a, CD18 and CD11b36 has been
also demonstrated. Acquisition of this last molecule also facilitates egression of plasma cells
through the capillary wall and leads to tumor dissemination. The high expression of VLA-4
in PCL, a requisite for invasiveness of leukemic cells because of the contact with its ligand
in capillary vessel wall, would increase extravasation of leukemic cells from the blood into
extravascular space35,37. Low expression of chemokine receptors CCR1, CCR2, and
CXCR4 has been observed in patients with active plasma cell disease as compared to those
with inactive disease38. In this regard, recent findings indicate that thalidomide exposure
induces down-regulation of CXCR4 and its ligand SDF-1alpha, which are involved in the
BM homing of myeloma cells39. However, although the CXCR4 inhibitor AMD 3100
disrupts the interaction of myeloma cells with the BM microenvironment resulting in an
increased number of circulating myeloma cells in mice40, it seems that AMD 3100 does not
induce either an increase in tumor progression or an engraftment at extramedullary sites in
the AMD 3100-treated mice compared with control mice40 or on the development of PCL.
Cytokines are also involved in PCL proliferation, particularly interleukin-6 (IL-6)41.
Primary and secondary PCL have spontaneous cell growth in culture, with increased growth
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when stimulated with exogenous IL-641. Autocrine IL-6 production triggered by interferon-
alpha (IFN-α) has been postulated42, based on a patient who developed PCL picture
triggered by this treatment, enforcing the particular potential cytokine network in the
pathogenesis of this entity. The same phenomenon has also been described with IL-3 that
up-regulates IL-6 receptors43. Finally, association with viral infections has been
hypothesized, with contradictory results44-46.
Consensus: Plasma cells from patients with PCL overlap in antigenic expression
with those of patients with MM. However, CD20 (higher), CD56 (lower), CD117
(lower) and HLA-DR (lower) may be useful for both discrimination of PCL from
MM and for follow-up studies. Further investigation of the pathogenetic role of
surface cell molecules resulting in extramedullary spread in this entity is clearly
warranted.
FISH and Cytogenetics
The molecular basis of PCL is poorly understood. Cytogenetic studies show that plasma
cells in primary PCL have a number of genetic abnormalities. More than 80% of patients
with PCL have hypodiploid or diploid cells which is associated with poor prognosis whereas
about 60% of patients with MM display hyperdiploidy, a favorable finding5. Chromosomal
abnormalities in PCL are summarized in Table 2. Results of these studies are very
heterogeneous, basically based in retrospective studies and unsorted samples.
Chromosome 13 deletion and monosomy are the most frequent features5,13. Alterations such
as monosomy 7, rarely seen in MM, has been observed in PCL47,48. Deletion of 17p13.1,
causing allelic loss of TP53, has been detected in almost 50% of primary PCL and in 75% of
secondary forms in one report. This deletion was complemented by coding mutations in
24% of patients with PCL7. The frequencies of IgH (14q32) translocations by FISH analysis
are common in both types of PCL with 87% and 82% in primary and secondary forms,
respectively. Thus, in a Mayo Clinic study the frequency of t(11;14) by FISH or by
informative karyotype in primary PCL was 71%. Importantly, the IgH translocation in PCL
involved chromosome 11 and cyclin D1 expression7. Conversely, no cases of t(4;14) or
t(14;16) were observed in primary PCL7. Interestingly, p53 loss due to mutation or deletion
was observed in 56% of patients with primary PCL and in 83% of patients with the
secondary form7. Translocation t(11;14) is a favorable prognostic factor in M; however, its
high prevalence in PCL suggests that this translocation when associated with high-risk
cytogenetics, such as loss of p53, confers a different prognosis. Of course, PCL may simply
be a completely different disease than MM, with different relevant high-risk factors. In the
French and British experience51,52, PCL also had significant differences when compared
with MM: a higher incidence of t(11;14), t(14;16) and monosomy 13, with similar incidence
of t(4;14).
Abnormalities in chromosome 1 are also frequent in PCL, particularly 1q21 amplification
(involving CKS1B overexpression)53 and del(1p21)54. The first finding was confirmed in all
primary PCL patients in a Spanish series by comparative genomic hybridization (CGH), as
well as losses on 13q, chromosome 16, 2q and 6p55.
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Certain genes, such as cMYC56, are overexpressed by a complex mechanisms, such as
cMYC56, in spite of the fact that only 15% of primary PCL have a cMYC translocation52,57.
Mutations in N-Ras and K-Ras show a similar frequency at diagnosis in PCL and in MM58.
Epigenetic changes, such as p16 inactivation, have also been described in primary PCL59,60
or global DNA hypomethylation of repetitive genomic sequences61. Gene-specific DNA
hypermethylation as either tumor suppressors, cell-cell signaling or as cell adhesion
molecules in PCL versus MM cells, may allow the clone to become independent of the bone
marrow microenvironment62. Interestingly, within the same cytogenetic group (i.e. t(4;14)
or t(11;14)) PCL samples were more hypermethylated in progression-related genes than the
corresponding MM cells62. A relative high incidence of PTEN deletion which results in Akt
activation has been observed in PCL and it has been suggested that PTEN loss can be
involved in the transition from MM to PCL.
Gene-expression profile and whole genome sequencing
Usmani et al recently described the experience in PCL with total therapy programs63. The
clinical outcomes were similar to those achieved with less intense therapy with an OS of
only 18 months. Importantly, the GEP was completed in 16/27 patients, and surprisingly
only 44% of patients with pPCL had a high risk signature defined by the GEP-70 model and
31% by the GEP-80 model63. Importantly, in the GEP analysis there was a tight clustering
within the pPCL cohort as opposed to non-pPCL suggesting distinct molecular and genomic
features in these groups. CD14 (cell-membrane LPS receptor), TNF receptor associated
factor 2 (TRAF2) and chemokine C-C motif ligand were among 203 genes differentially
expressed in pPCL hypothesizing myeloid differentiation of plasma cells during leukemic
development63.
On the other hand, Eagan et al recently described whole genome sequencing (WGS) in serial
samples from a single patient through different points in the natural history, including
development of sPCL64. This methodology with WGS may provide unique insights into
potential mechanisms of PCL development.
Consensus: Cytogenetics and FISH studies on bone marrow are mandatory in all
patients with suspected PCL. On cytogenetics the karyotype is frequently complex
and demonstrates hypodiploidy. With FISH analysis, careful attention should be
paid to the most frequent reported alterations: (t(11;14) as well as to chromosome 1
and 17 abnormalities, particularly 1q+ and del17p. Additional molecular research
aimed at understanding the development of primary PCL and transformation of
MM into secondary PCL is needed.
RESPONSE TO THERAPY AND SURVIVAL
The survival of patients with pPCL is short. In seven series, historically median survival,
without novel therapies, has ranged from 6.8 to 12.6 months3-7,11-13. Furthermore, the
median survival of 231 patients from a recently published epidemiology study was only 4
months6. Of note, the survival rate at 5 years from diagnosis is less than 10% in all series.
The best survival data, incorporating hematopoietic stem-cell transplantation, reported a
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median survival longer than 3 years65. Unfortunately, the significant improvement in
survival observed in MM in the past decade has not been seen in PCL6.
These discouraging survival results in primary PCL are due to two facts: 1) its aggressive
presentation with severe complications leading to early death within the first months from
diagnosis, and 2) the lack of effective therapy to achieve sustained responses. Early
mortality is still of concern and reflects the aggressiveness of the disease. In the French
cohort, 11 of 40 patients died within the first month after diagnosis51. Unfortunately, data
from transplantation registries or clinical trials have a systematic bias to exclude patients not
fulfilling the entry criteria and/or experiencing early death. Secondary PCL is usually a
terminal event with a median OS of only one month3.
Criteria of Response
There are no specific response criteria for PCL. Thus, the general MM response criteria have
been applied without distinctive considerations. Due to the leukemic nature of the disease as
well as the relative higher percentage of light-chain only (Bence Jones) and oligosecretory
forms, the importance of a precise plasma cell evaluation in blood and bone marrow by
morphology and flow cytometry as well as the measurement of the serum free-light chain
should be considered. Thus, the evaluation of response in primary PCL should combine
acute leukemia66 and MM requirements67,68 (Table 3). The impact of a rapid clearance in
peripheral and/or bone marrow malignant plasma cells has not been evaluated. It is
reasonable to suggest that in PCL, the disappearance of peripheral blood plasma cells and a
bone marrow plasma cell count <5% should be required to qualify for CR after
hematological recovery. Complete clearance by conventional morphology in bone marrow
for complete remission is required (Table 3), and flow cytometry should be necessary to
define “stringent” CR. In addition, the high frequency of extramedullary involvement
justifies evaluation of the patients by imaging techniques such as magnetic resonance
imaging (MRI) and, particularly, FDG positron emission tomography/computer tomography
(PET/CT).
Relapse from CR is defined as the reappearance of M-protein in patients in CR,
extramedullary disease, reappearance of peripheral blood plasma cells at any level or
increase in bone marrow plasma cells more than 10%. In contrast to MM, immediate therapy
should be initiated when any evidence of relapse is documented.
Consensus:
Improvement in PCL outcomes need to be focus on 1) reducing early mortality and
2) improving long term disease control. In the absence of specific response criteria
for PCL, response to therapy has been evaluated according to MM criteria. Given
the primarily leukemic nature of the disease and the frequency of oligo/non-
secretory forms, the evaluation of response should combine acute leukemia and
MM criteria. Measurement of immunophenotypic residual disease is needed when
there is no evidence of plasma cell infiltration with routine morphologic evaluation.
Finally, a careful evaluation of extramedullary disease at diagnosis and at response
evaluation is required for all PCL patients.
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THERAPEUTIC OPTIONS
Conventional regimens
The results of treatment with combinations of alkylating agents, mainly melphalan, and
glucocorticoids, are unsatisfactory. Despite an overall response rate (ORR) ranging from 23
to 67%, the median OS has been less than one year in all the reported series3-5,11-13. In one
study, the failure to achieve 50% clearance of blood plasma cells within 10 days after
treatment initiation was a predictor of no response4. The addition of more agents, such as
VAD (vincristine, doxorubicin and dexamethasone) or the VCMP regimen (vincristine,
carmustin, melphalan and prednisone) alternating with VBAP (vincristine, carmustin,
doxorubicin and prednisone) modestly improved the results in terms of response rate and
OS4,5,7.
Investigators have also attempted to improve outcomes with standard regimens such as
HyperCVAD (hyper-fractionated cyclophosphamide, vincristine, doxorrubicin,
dexamethasone)69.
Novel drugs: Thalidomide/Lenalidomide
Anecdotal reports in small series showed a potential role of thalidomide in PCL70,71, but
without confirmation thus far72. Severe cardiac and pulmonary toxicities have been
described73,74.
Lenalidomide, a more potent immunomodulatory drug resulted in only transient
responses75-77. Combination of lenalidomide with melphalan and glucocorticoids has also
been used78, achieving a transient PR in one case.
Musto et al. have presented the results of a prospective multicenter phase II trial of
lenalidomide/dexamethasone in first line in 23 patients with primary PCL79. Patients
received lenalidomide 25 mg for days 1-21 and weekly dexamethasone 40 mg in a 28 day
cycle as primary induction therapy for 4 cycles and if eligible for ASCT (autologous stem
cell transplantation) could proceed to ASCT or continue long term primary therapy. The
initial ORR was 60% and, with a median follow-up of 15 months, the OS and PFS were
65.2% and 52.1%, respectively.
Novel Therapies: Bortezomib
The proteosome inhibitor bortezomib has shown clinical activity in both primary and
secondary PCL80,81. An Italian group reported the results of a retrospective analysis on
twelve evaluable patients with pPCL at relapse and sPCL treated with a bortezomib based
combination82. Response rate was 92%, including two complete responses (CR). Responses
did not appear to be influenced by previous therapy, including autologous stem-cell
transplantation (ASCT). The median progression-free survival (PFS) and OS after
bortezomib were 8 months and 12 months, respectively. The same group described a similar
high response in untreated pPCL treated at time of diagnosis with bortezomib and various
combinations (VD, n=3; VTD, n =2; PAD, n =6; MPV, n=1). There was a high overall
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response rate (79%) including 28% CR and 83% of patients were alive if the response was
consolidated with stem-cell transplantation, but the follow-up is still very short83.
Another single-institution experience has described a series of 25 patients (13 pPCL; 12
sPCL) with a high response rate of 16 out of 18 patients treated with a bortezomib-based
regimen. Importantly, the OS of patients exposed to bortezomib was 28 months compared to
4 months in those who did not receive bortezomib at induction84.
The efficacy of the combination of bortezomib with dexamethasone and melphalan85 or
doxorubicin82,86 has also been reported in selected smaller case reports and series.
Bortezomib and dexamethasone has been shown to be useful in three patients with primary
PCL, t(4;14) and CD27 expression87.
High dose therapy/stem cell transplantation
Considering the poor prognosis of this form of clonal plasma cell dyscrasia, intensification
with high-dose therapy followed by autologous stem cell rescue should be offered, provided
that age and clinical condition do not preclude this approach. In the Mayo Clinic series,
patients who received ASCT had a longer median OS when compared with those who
received chemotherapy alone (34 versus 11 months)7, although at least part of this survival
benefit is obviously due to a selection bias in favour of the transplant group.
The largest study in the transplantation setting is the retrospective report by the European
Group for Blood and Marrow Transplantation88, reporting data on 272 patients with primary
PCL. At the time of conditioning for transplantation, a higher proportion of patients with
PCL than MM were in CR (25.5% versus 11.9%). Also, patients with PCL achieved a higher
CR rate at 100 days after ASCT (41.2% vs. 28.2%), but a selection bias cannot be excluded.
This response pattern is consistent with the clinical behaviour of high risk myeloma, which
tends to have higher initial response rates to induction therapy and ASCT89; however, they
also have shorter response duration with rapid relapse. The median PFS was 14.3 months in
PCL and 27.4 months in MM. This is translated into significantly shorter OS in the PCL
group (median of 25.7 versus 62.2 months), irrespective of the degree of response achieved,
reflecting a more aggressive minimal residual disease in patients with PCL. In addition, the
fact that a significant proportion of patients with PCL potentially eligible for ASCT could
die or develop progression within the first few months after diagnosis51, precluding the
high-dose procedure, represents an important bias in favour of transplant results. In
summary, despite the relative good response achieved in selected patients with PCL who
respond to initial treatment and receive intensification with ASCT, it usually does not
translate into a prolonged survival. Therefore, other therapeutic approaches should be
explored, such as the use of the new drugs in induction, consolidation or maintenance or a
subsequent reduced-intensity allogeneic transplant81.
The CIBMTR reported a PFS and OS at 3 years of 34% and 62% respectively, in 97 patients
with pPCL who underwent ASCT. This experience supports the role of ASCT in transplant
eligible patients and offers an opportunity for relatively prolonged remission. These results
for the first time demonstrated survival beyond 3 years in a proportion of selected patients65.
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Tandem ASCT could result in an improved depth and duration of remission. In this regard,
in Total Therapy (TT) programs, timing of onset and eventual rate of CR were virtually
identical for patients with or without PCL. However, median OS (1.8 years) and PFS (0.8
years) were inferior to those of the non-PCL group as a whole. Significant advances in
clinical outcomes were observed among non-PCL patients with the transitions from TT1 to
TT2, to TT3, but such advances were not observed in PCL patients63. Other strategies to
consolidate after first ASCT, other than second ASCT, including combination regimens of
VTD, RD or VRD may also play a role and need further evaluation. The addition of
aggressive long-term maintenance therapy with lenalidomide or novel lenalidomide-based
combinations provides yet another potential strategy to improve duration of remission. The
significant PFS benefit reported by CALBG 10014 and IFM with maintenance lenalidomide
suggest that maintenance lenalidomide therapy could be an attractive possibility to be
investigated in PCL90,91. Importantly, relapses may occur very early after ASCT and
therefore it is worth considering early initiation of maintenance therapy, in the first 30-60
days, as soon as a stable engraftment is documented.
Allogeneic Stem Cell Transplantation
A retrospective report of 147 patients with primary PCL from the CIBMTR experience
showed that 19 of the 50 patients (39%) who underwent allogeneic transplantation were
alive at 3 years65. Few of these patients had received novel agents (thalidomide,
lenalidomide or bortezomib) as part of their induction regimen. Progressive disease
accounted for 22% of the deaths in the allogeneic transplant group, compared to 85% of the
deaths in the ASCT group.
The EBMT recently described their experience with 85 patients who underwent allogeneic
transplantation in comparison to 411 patients who underwent autologous SCT for PCL. PFS
curves with the myeloablative and RIC allo-SCT possibly crossed the ASCT curve between
2 and 4 years, but with similar OS at 5 years. As seen in previous experiences with allo-SCT
described by the CIBMTR, there was a high early mortality; however, there was also a clear
plateau in survival at 20%92.
Careful selection of patients undergoing either myeloablative or reduced-intensity
conditioning (mainly by age), and incorporating new drugs in induction and consolidation/
maintenance could potentially further exploit the alloreactive immunotherapeutic effect.
Consensus: The diagnosis of PCL needs to be made in a timely manner and
immediate therapy initiated. The goal of induction therapy is to achieve rapid
cytoreduction to minimize the risks contributing to early death. Intensive
chemotherapy with alkylating agents or anthracyclines such as HyperCVAD or
PACE regimens and bortezomib-based combinations (VTD-PACE [cisplatin,
doxorubicin, cyclophosphamide, and etoposide], HyperCVAD-VD or PAD) can
meet these goals. Although the data are still limited, the use of bortezomib likely
improves disease outcome and this drug will likely become the backbone in the
treatment of PCL. Strategies to improve long term survival include the
incorporation of high-dose therapy with autologous SCT. Much of the
improvement in outcomes with novel therapies and ASCT have been observed in
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primary PCL, but without significant improvement in secondary PCL. The role of
consolidation and maintenance therapy needs to be evaluated. The impact of
tandem autologous cell transplant and allogeneic transplantation also remains to be
defined.
In patients younger than 50 years of age with a suitable donor, a myeloablative
allogeneic transplantation can be considered. Otherwise, a tandem transplant with
an ASCT followed by a reduced-intensity conditioning allogeneic transplantation if
a related or and unrelated donor is available (Figure 3) can be considered.
In patients not candidates for HDT/SCT, a bortezomib-based induction regimen
(MPV, VRD or VTD) in order to achieve a rapid response appears to be the best
choice (Figure 4). However, these recommendations are supported by limited data
and are mainly based on expert opinion.
Treatment in secondary PCL or relapsed primary PCL depends on the type of and
response to previous therapy. Fit patients may be candidates for bortezomib-based
regimens or intensive chemotherapy (i.e. HyperCVAD or Dexamethasone-PACE)
or early phase clinical trials in eligible patients, followed by stem-cell
transplantation if suitable (Figure 5)
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Figure 1.
Abdominal tomography showing a focal lesion (40 mm), highlighted by the arrow,
suggestive of metastasic infiltration of the liver in a patients with plasma cell leukemia.
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Figure 2.
PET/CT-scan of a patient with primary PCL showing focal bone lesion with increased
uptake of FDG in vertebrae, ribs and pelvis.
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Figure 3.
Conventional morphology in plasma cell leukemia cases shows bone marrow infiltration
(Panel A), with circulating plasma cells (Panel B) and frequent extramedullary involvement,
as hepatic infiltration (Panel C).
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Figure 4.
Treatment algorithm for primary plasma cell leukemia
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Figure 5.
Treatment algorithm for secondary plasma cell leukemia or relapsed primary plasma cell
leukemia
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Table 1
Main clinical and laboratory features of seven retrospective series of patients with primary plasma cell
leukemia.
Noel and
Kyle
(1987)
Dimopoulos et
al (1994)
Garcia-
Sanz et al
(1999)
Tiedemann et
al (2008)
Colovic et
al (2008)
Peijing et
al (2009)
Pagano et
al (2011)
Number of patients 25 27 26 41 30 22 73
Median age (years) 53 57 65 54.5 60 49.5 NA
Sex, M/F 15/10 NA 12/14 24/17 22/8 14/8 43/30
Lytic bone lesions (%) 44 NA 48 35 60 44.4 64
Extramedullary
involvement (%)
Liver 52 32 0 32 56 44.4 23
Spleen 44 18 0 18 53 33.3 18
Lymph nodes 12 6 11 6 3 NA 4
Other NA NA NA NA NA NA 14
M-protein type (%)
IgG 12.5 52 54 28 53 54.5 30
IgA 25 15 4 13 23 9.1 8
IgD 6 0 8 2 3 0 3
Light chain 44 28 31 41 20 27.3 30
Nonsecretory 12.5 7 4 8 0 9.1 18
Hemoglobin
<10 g/dL (%)
>50 82 54 >50 100 >50 48
Platetelet count
< 100 × 109/L (%)
>50 67 48 >50 100 >50 NA
High β2-microglobulin
(%)
NA 91 65 50 64 50 100
High LDH (%) NA 63 48 50 37 NA 52
Response to
treatment (%)
47 37 38 NA NA 45.5 55
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Table 2
Cytogenetics data available in plasma cell leukemia series
Cytogenetics
abnormalities (%)
Garcia-
Sanz et al
(1999)
Dimopoulos et
al (1994)
Tiedemann et al
(2008)
Pagano et al
(2011)
Avet-Loiseau
et al (2001)
Chiecchio et al
(2009)
Hypodiploidy 41 60 12.2 47 41.6
Hyperdiplody 0 4.9 8.8 33.3
Complex karyotype 92 54.5 34.2 58.8 66.7
del(13q14) or monosomy 84 50 85 19 68 58
del(17p13) 50 7.3 11.8 25
t(11;14) 71 19.5 33 42
t(4;14) 0 0 12 8.3
t(14;16) 0 0 16 25
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Table 3
Response criteria for plasma cell leukemia
Category Bone marrow
criteria1
Peripheral
blood criteria1
Serologic
criteria2
Other criteria
Stringent
Complete
Remission
(sCR)
-Bone marrow plasma
cells <5%
and
-No malignant plasma
cell by flow cytometry
-No plasma cells
in peripheral
blood by flow
cytometry
-Negative serum
and urine
immunofixation
-Normal serum
FLC ratio
-Absence of
extramedullary
disease
Complete
remission (CR)
-Bone marrow plasma
cells <5%
- No plasma cells
in peripheral
blood
-Negative serum
and urine
immunofixation3
-Absence of
extramedullary
disease.
Very Good
Partial
response
(VGPR)
-Bone marrow plasma
cells <5%
-No plasma cells
in peripheral
blood
-≥90% reduction
of serum M-
protein, and
-24-h urinary M-
protein <100 mg
per 24 h4
-Absence of
extramedullary
disease.
Partial
response (PR)
-Bone marrow plasma
cells to 5% to 25%
-Peripheral
plasma cell from
1% to 5%
-≥50% reduction
of serum M-
protein and
-Reduction in 24-
h urinary M-
protein by ≥90%
and <200 mg per
24 h5
-≥50% reduction
in the size of
extramedullary
disease
Stable disease
(SD) Not meeting the criteria of either partial response or progressive disease
Progressive
disease (PD)
>25% increase in
plasma cells in a
bone marrow aspirate
or absolute increase
≥10%
-Plasma cells
>5% absolute
increase in
peripheral blood
->25% increase
in the level of the
serum
monoclonal
paraprotein with
an absolute
increase ≥5 g/L
->25% increase
in the 24h
urinary light
chain excretion
with and
absolute
increase ≥200
mg/24 hours
-Hypercalcemia
-Definite increase
in lytic bone
lesions
-Definite increase
in the size or
number of
extramedullary
disease
Relapse from
CR
-More than 10%
increase in bone
marrow plasma cells
Reappearance of
peripheral blood
plasma cells at
any level
-Reappearance
of original M-
protein in serum
and/or urine
immunofixation
-Any
extramedullary
disease
1
It is recommended that at least 200 leukocytes on blood smears and 500 nucleated cells on marrow smears be counted.
2
It should be maintained for a minimum of 6 weeks. In case of discrepancy or undetectable serological parameter, the patient must be classified
according to bone marrow criteria.
3
If the serum and urine M-protein are unmeasurable, a normal serum kappa/lambda FLC ratio is also required.
4
If the serum and urine M-protein are unmeasurable, a ≥90% decrease in the difference between involved and uninvolved FLC levels is required
instead of the M-protein.
5
If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required
instead of the M-protein.
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